Investigating Apatorsen in Advanced Non-Squamous Non–Small Cell Lung Cancer

Phase 2 Trial
Spruce
Investigating Apatorsen in Advanced Non-Squamous Non-Small Cell Lung Cancer

An investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating apatorsen in combination with carboplatin and pemetrexed in patients with previously untreated, advanced, non-squamous, non–small cell lung cancer (NSCLC)

About apatorsen and the ORCA Program

Apatorsen is a once-weekly intravenous (IV) drug designed to inhibit production of heat shock protein 27 (Hsp27) to disable cancer cells' defenses and overcome treatment resistance. Both the potential single-agent activity of apatorsen and its synergistic activity with cancer treatments may increase the overall benefit of existing therapies and augment the durability of treatment outcomes, which could lead to increased patient survival.

The ORCA™ (**O**ngoing Studies Evaluating Treatment **R**esistance in **CA**ncer) Program encompasses clinical studies of apatorsen aiming to demonstrate whether inhibition of Hsp27 may lead to improved prognoses and treatment outcomes for patients with cancer.

About the Spruce Trial

Study population: Patients with previously untreated advanced NSCLC, excluding squamous cell and small cell histologies

Primary objective: To compare the progression-free survival (PFS) of apatorsen plus carboplatin/pemetrexed therapy to placebo plus carboplatin/pemetrexed in patients with previously untreated advanced non-squamous NSCLC

Secondary objectives:

- To compare the objective response rate (ORR) in each treatment group
- To compare overall survival (OS) in each treatment group
- To evaluate safety of apatorsen in combination with carboplatin/pemetrexed

Study design



Key inclusion criteria

- Histologic or cytologic diagnosis of advanced NSCLC, excluding squamous cell and small cell histologies. Tumors with mixed NSCLC histologies are eligible, as long as the predominant histology is not squamous. If small-cell elements are present or not otherwise specified (NOS) histologically, the patient is not eligible
- Recurrent or stage IV disease (according to American Joint Committee on Cancer [AJCC] staging system v7.0)
- No prior systemic chemotherapy, immunotherapy, targeted therapy, or biological therapy; adjuvant therapy is allowed as long as the interval from end of adjuvant therapy until disease progression was >12 months
- No prior radiation therapy to the whole pelvis or to ≥25% of the total bone marrow area. Radiation therapy must be completed at least 2 weeks prior to randomization. Must have recovered from acute adverse effects prior to randomization
- At least one measurable lesion according to RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1
- Adequate bone marrow, hepatic, and renal function

Key exclusion criteria

- Known ALK translocation and EGFR-activating mutations where first-line treatment with targeted kinase inhibitor therapy is more appropriate
- Known central nervous system (CNS) disease other than neurologically stable, treated brain metastases—defined as metastasis having no evidence of progression or hemorrhage after treatment and no ongoing requirements for corticosteroids (eg, dexamethasone) for at least 2 weeks
- Cardiac disease currently or within the last 6 months as defined by New York Heart Association (NYHA) ≥class II
- Currently receiving therapeutic anticoagulation
- Pregnant or lactating
- Any serious, active underlying medical condition that would impair the ability of the patient to receive study treatment, such as diabetes mellitus or infection
- Active second malignancy (except non-melanomatous skin or superficial bladder cancer) defined as requiring current need for cancer therapy or at high risk of recurrence (>30%) during the study

ORCA
Ongoing Studies Evaluating Treatment Resistance in CAncer

For more information on the Spruce Trial, please visit www.clinicaltrials.gov (Identifier: NCT01829113) or contact Sarah Cannon Research Institute (877-MY-1-SCRI), the study sponsor.

For more information on apatorsen and the ORCA Program, please visit www.ORCAtrials.com
Apatorsen is not approved for commercial use and is only available for investigational use in approved clinical trials.

OncoGenex™